Streetbeat News

Products Services

BHC

Salix Pharmaceuticals, a subsidiary of Bausch Health Companies Inc. (NYSE:BHC), has released its third edition of the Liver Health Trends Report. The report shows a 9% increase in chronic liver disease (CLD) and cirrhosis mortality, making these the ninth leading cause of death in the U.S. in 2021. The report also highlights ongoing disparities in CLD care, including a shortage of liver specialists in rural areas. The report is based on a survey of 400 health care providers, qualitative interviews, and secondary research from peer-reviewed publications.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:11 pm

BHC

Salix Pharmaceuticals, a subsidiary of Bausch Health Companies Inc. (NYSE:BHC), has released its third Liver Health Trends Report, which shows a 9% increase in chronic liver disease (CLD) and cirrhosis mortality in the US in 2021. The report also highlights ongoing disparities in CLD care, including a shortage of liver specialists in rural areas. The report is based on a survey of 400 health care providers, qualitative interviews, and secondary research from peer-reviewed publications.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:10 pm

MAIA

Maia Biotechnology announced that its lead asset, THIO, demonstrated potent anticancer activity in gliomas, a type of aggressive brain tumor. THIO was evaluated in various in vitro and in vivo models of gliomas.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:08 pm

CATX

Perspective Therapeutics (NYSE:CATX) announced two upcoming investigator-initiated trials (IIT) presented at the North American Neuroendocrine Tumor Society 2023 Symposium. The trials are Phase 1 and Phase 1/2 trials of Pb-212-VMT-alpha-NET in patients with metastatic or inoperable somatostatin receptors positive tumors and GI neuroendocrine tumors respectively. Enrollment for both studies is expected to commence in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:07 pm

ELYS

Elys Game Technology, Corp. (NASDAQ:ELYS) announced the expansion of its footprint in Washington, D.C. with the addition of a third sportsbook location, Grand Central Sportsbook on H Street. The new location builds on the success of both the Grand Central Restaurant and Sportsbook and the Cloakroom Gentlemen's Club Over Under Sportsbook Lounge. The company is actively seeking opportunities for program expansion and is positioned to capitalize on the burgeoning market as more states embrace the small business sportsbook concept.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:07 pm

ACCD

AON

LLY

NVO

A survey by Accolade Inc and Savanta indicates that US employers are increasingly willing to include obesity medications like Novo Nordisk's Wegovy in their health coverage plans. The survey found that 43% of employers could potentially cover these drugs in 2024, up from the current 25%. Eli Lilly's Mounjaro, another GLP-1 diabetes drug, is also expected to gain approval for weight loss applications in the US this year. Aon Plc highlighted the economic implications of this trend, attributing a one percentage point rise in the anticipated 8.5% increase in employer healthcare costs to the uptick in employee utilization of weight-loss drugs.

Portfolio Pulse from Vandana Singh

October 10, 2023 | 12:06 pm

IMAB

I-Mab and ABL Bio have announced updates on their ongoing Phase 1 study of bispecific antibody TJ-L14B/ABL503. Among 14 efficacy-evaluable patients, one achieved a complete response, one had a partial response and two unconfirmed partial responses. The maximum tolerated dose has not yet been reached. Patent rights for TJ-L14B/ABL503 have been secured in Eurasia until 2039.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:06 pm

TSHA

Taysha Gene Therapies has announced two poster presentations on TSHA-102 in Rett Syndrome at the upcoming European Society of Gene & Cell Therapy Annual Congress. This could potentially increase visibility and interest in the company's work.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:04 pm

CELZ

Creative Medical Technology Holdings has received IRB approval for an FDA cleared Phase 1/2 clinical trial of StemSpine. The trial will use AlloStem, a novel cell therapy, to treat chronic lower back pain.

Portfolio Pulse from Bill Haddad

October 10, 2023 | 12:04 pm

ECOR

ElectroCore, Inc. (NASDAQ:ECOR) has announced top line data from two clinical trials presented at the 2023 World Stroke Congress. The trials suggest that non-invasive Vagus Nerve Stimulation (nVNS) is safe and effective for the treatment of acute neurological injuries. The VANQUISH trial showed a significant reduction in pain and a decrease in the use of acute pain medications, including opioids, in patients with Subarachnoid Hemorrhage. The NOVIS trial, which will complete recruitment in 2023, is studying the efficacy of nVNS in the acute treatment of Ischemic Stroke.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:03 pm